Symbols / NRXP $2.08 +11.83%
NRXP Chart
About
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital; and has as a partnership with neurocare Group AG to create a nationwide network of clinics to offer integrated neuroplastic care for the treatment of Depression, PTSD, and other serious mental health disorders. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 66.29M |
| Enterprise Value | 61.52M | Income | -38.06M | Sales | 242.00K |
| Book/sh | -0.93 | Cash/sh | 0.26 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | 16.00 | PEG | — |
| P/S | 273.94 | P/B | -2.24 | P/C | — |
| EV/EBITDA | -4.05 | EV/Sales | 254.19 | Quick Ratio | 0.26 |
| Current Ratio | 0.29 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.31 | EPS next Y | 0.13 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-17 | ROA | -97.83% |
| ROE | — | ROIC | — | Gross Margin | 59.92% |
| Oper. Margin | -17.02% | Profit Margin | 0.00% | Shs Outstand | 31.87M |
| Shs Float | 20.35M | Short Float | 8.18% | Short Ratio | 4.25 |
| Short Interest | — | 52W High | 3.84 | 52W Low | 1.58 |
| Beta | 1.99 | Avg Volume | 992.33K | Volume | 2.03M |
| Target Price | $38.00 | Recom | Strong_buy | Prev Close | $1.86 |
| Price | $2.08 | Change | 11.83% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$38.00
Mean price target
2. Current target
$1.96
Latest analyst target
3. DCF / Fair value
$1.69
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.96
Low
$25.00
High
$48.00
Mean
$38.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-17 | main | D. Boral Capital | Buy → Buy | $34 |
| 2026-03-16 | main | D. Boral Capital | Buy → Buy | $34 |
| 2026-03-09 | main | D. Boral Capital | Buy → Buy | $34 |
| 2026-03-03 | main | HC Wainwright & Co. | Buy → Buy | $45 |
| 2026-02-18 | reit | BTIG | Buy → Buy | $25 |
| 2026-02-17 | main | D. Boral Capital | Buy → Buy | $34 |
| 2026-01-15 | reit | BTIG | Buy → Buy | $25 |
| 2026-01-05 | main | D. Boral Capital | Buy → Buy | $34 |
| 2026-01-02 | main | Ascendiant Capital | Buy → Buy | $48 |
| 2025-12-16 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-12-03 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-12-03 | reit | BTIG | Buy → Buy | $25 |
| 2025-12-02 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-11-17 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-11-10 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-10-30 | main | Ascendiant Capital | Buy → Buy | $47 |
| 2025-10-21 | main | D. Boral Capital | Buy → Buy | $34 |
| 2025-10-16 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-10-01 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-09-29 | main | D. Boral Capital | Buy → Buy | $34 |
- FDA review finds no issues with preservative-free ketamine, dropping additive - Stock Titan ue, 17 Mar 2026 11
- NRx Pharmaceuticals' (NRXP) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat Mon, 16 Mar 2026 19
- Why Is NRx Pharma Stock Gaining Monday? - NRX Pharmaceuticals (NASDAQ:NRXP) - Benzinga Mon, 16 Mar 2026 17
- NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting - markets.businessinsider.com Mon, 16 Mar 2026 12
- HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD - GlobeNewswire Mon, 09 Mar 2026 11
- Why Did NRXP Stock Surge 21% Pre-Market Today? - Stocktwits Wed, 14 Jan 2026 08
- NRXP Analyst Maintains Buy Rating with $34 Target | NRXP Stock N - GuruFocus Wed, 03 Dec 2025 08
- NRx Pharmaceuticals Addresses Nasdaq Meeting Compliance Requirements - The Globe and Mail Sat, 17 Jan 2026 08
- New Strong Sell Stocks for January 27th - Yahoo Finance ue, 27 Jan 2026 08
- NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset - TechStock² Wed, 14 Jan 2026 08
- NRx Pharmaceuticals Completes Repayment of $5.4 Million Debt, Positioning Company for Growth in 2026 - Quiver Quantitative hu, 18 Dec 2025 08
- Biotech wipes out final $5.4M debt as it pursues depression treatments - Stock Titan hu, 18 Dec 2025 08
- NRx Pharmaceuticals (NASDAQ:NRXP) Stock Rating Upgraded by Zacks Research - MarketBeat Wed, 04 Mar 2026 08
- NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer - GlobeNewswire Mon, 02 Mar 2026 12
- New Analyst Forecast: $NRXP Given $25 Price Target | NRXP Stock News - Quiver Quantitative hu, 15 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 40000 | 65600 | — | Purchase at price 1.64 per share. | JAVITT JONATHAN C | Chairman of the Board | — | 2024-12-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -23.23M | -29.80M | -44.59M | -94.43M |
| TotalUnusualItems | -1.66M | -230.00K | 4.84M | 1.39M |
| TotalUnusualItemsExcludingGoodwill | -1.66M | -230.00K | 4.84M | 1.39M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -25.13M | -30.15M | -39.75M | -93.06M |
| ReconciledDepreciation | 5.00K | 5.00K | 4.00K | 2.00K |
| EBITDA | -24.89M | -30.02M | -39.75M | -93.04M |
| EBIT | -24.90M | -30.03M | -39.75M | -93.05M |
| NetInterestIncome | -186.00K | 374.00K | 249.00K | -18.00K |
| InterestExpense | 230.00K | 120.00K | 0.00 | 18.00K |
| InterestIncome | 44.00K | 494.00K | 249.00K | 0.00 |
| NormalizedIncome | -23.47M | -29.92M | -44.59M | -94.45M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -25.13M | -30.15M | -39.75M | -93.06M |
| TotalExpenses | 18.50M | 27.59M | 44.34M | 94.43M |
| TotalOperatingIncomeAsReported | -18.50M | -27.84M | -44.34M | -115.80M |
| DilutedAverageShares | 10.64M | 7.58M | 6.58M | 4.69M |
| BasicAverageShares | 10.64M | 7.58M | 6.58M | 4.69M |
| DilutedEPS | -2.36 | -3.98 | -6.10 | -74.40 |
| BasicEPS | -2.36 | -3.98 | -6.10 | -74.40 |
| DilutedNIAvailtoComStockholders | -25.13M | -30.16M | -39.75M | -348.88M |
| NetIncomeCommonStockholders | -25.13M | -30.16M | -39.75M | -348.88M |
| OtherunderPreferredStockDividend | 0.00 | 9.00K | 0.00 | 255.82M |
| NetIncome | -25.13M | -30.15M | -39.75M | -93.06M |
| NetIncomeIncludingNoncontrollingInterests | -25.13M | -30.15M | -39.75M | -93.06M |
| NetIncomeContinuousOperations | -25.13M | -30.15M | -39.75M | -93.06M |
| TaxProvision | 0.00 | 0.00 | ||
| PretaxIncome | -25.13M | -30.15M | -39.75M | -93.06M |
| OtherIncomeExpense | -6.44M | -2.94M | 4.33M | 1.39M |
| OtherNonOperatingIncomeExpenses | -4.78M | -2.71M | -505.00K | -21.37M |
| SpecialIncomeCharges | -250.00K | 4.58M | -307.00K | |
| OtherSpecialCharges | 250.00K | 21.25M | ||
| RestructuringAndMergernAcquisition | 0.00 | -4.58M | -20.94M | |
| GainOnSaleOfSecurity | -1.66M | 20.00K | 255.00K | 1.69M |
| NetNonOperatingInterestIncomeExpense | -186.00K | 374.00K | 249.00K | -18.00K |
| InterestExpenseNonOperating | 230.00K | 120.00K | 0.00 | 18.00K |
| InterestIncomeNonOperating | 44.00K | 494.00K | 249.00K | 0.00 |
| OperatingIncome | -18.50M | -27.59M | -44.34M | -94.43M |
| OperatingExpense | 18.50M | 27.59M | 44.34M | 94.43M |
| OtherOperatingExpenses | -1.20M | 250.00K | -771.00K | |
| ResearchAndDevelopment | 6.20M | 13.37M | 17.03M | 20.26M |
| SellingGeneralAndAdministration | 13.51M | 14.22M | 27.31M | 74.94M |
| GeneralAndAdministrativeExpense | 13.51M | 14.22M | 27.31M | 74.94M |
| OtherGandA | 13.51M | 14.22M | 27.31M | 74.94M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 14.59M | 8.39M | 6.64M | 5.88M |
| ShareIssued | 14.59M | 8.39M | 6.64M | 5.88M |
| NetDebt | 5.13M | 4.57M | ||
| TotalDebt | 6.58M | 9.16M | 10.53M | 518.00K |
| TangibleBookValue | -23.22M | -11.74M | 7.41M | 20.81M |
| InvestedCapital | -16.65M | -2.58M | 17.93M | 21.32M |
| WorkingCapital | -18.56M | -12.16M | 10.21M | 20.79M |
| NetTangibleAssets | -23.22M | -11.73M | 7.41M | 20.81M |
| CommonStockEquity | -23.22M | -11.74M | 7.41M | 20.81M |
| PreferredStockEquity | 3.00K | |||
| TotalCapitalization | -18.21M | -11.73M | 10.23M | 20.81M |
| TotalEquityGrossMinorityInterest | -23.22M | -11.73M | 7.41M | 20.81M |
| StockholdersEquity | -23.22M | -11.73M | 7.41M | 20.81M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -3.00K | 0.00 | |
| OtherEquityAdjustments | -3.00K | |||
| RetainedEarnings | -278.27M | -253.15M | -223.00M | -183.24M |
| AdditionalPaidInCapital | 255.03M | 241.41M | 230.34M | 203.99M |
| CapitalStock | 15.00K | 11.00K | 67.00K | 59.00K |
| CommonStock | 15.00K | 8.00K | 67.00K | 59.00K |
| PreferredStock | 0.00 | 3.00K | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 26.87M | 19.05M | 18.41M | 11.92M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 5.01M | 0.00 | 2.82M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 5.01M | 2.82M | ||
| LongTermDebt | 5.01M | 2.82M | ||
| CurrentLiabilities | 21.86M | 19.05M | 15.59M | 11.92M |
| OtherCurrentLiabilities | 5.64M | 17.00K | 37.00K | 4.87M |
| CurrentDebtAndCapitalLeaseObligation | 1.57M | 9.16M | 7.70M | 518.00K |
| CurrentDebt | 1.57M | 9.16M | 7.70M | 518.00K |
| OtherCurrentBorrowings | 1.57M | 9.16M | 7.70M | 518.00K |
| CurrentNotesPayable | 0.00 | 518.00K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 577.00K | 835.00K | ||
| CurrentProvisions | 4.71M | |||
| PayablesAndAccruedExpenses | 9.37M | 9.04M | 7.84M | 6.53M |
| CurrentAccruedExpenses | 5.24M | 4.40M | 5.77M | 2.84M |
| Payables | 4.13M | 4.63M | 2.08M | 3.69M |
| AccountsPayable | 4.13M | 4.63M | 2.08M | 3.69M |
| TotalAssets | 3.65M | 7.32M | 25.82M | 32.73M |
| TotalNonCurrentAssets | 349.00K | 431.00K | 21.00K | 15.00K |
| OtherNonCurrentAssets | 349.00K | 431.00K | 21.00K | 15.00K |
| CurrentAssets | 3.30M | 6.88M | 25.80M | 32.71M |
| PrepaidAssets | 1.86M | 2.28M | 5.73M | 5.11M |
| Receivables | 0.00 | 6.00K | 7.00K | 0.00 |
| OtherReceivables | 6.00K | 7.00K | ||
| AccountsReceivable | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 1.44M | 4.59M | 20.05M | 27.61M |
| CashAndCashEquivalents | 1.44M | 4.59M | 20.05M | 27.61M |
| CashFinancial | 20.05M | 27.61M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -10.64M | -21.66M | -39.77M | -37.71M |
| RepaymentOfDebt | -8.57M | -4.04M | -518.00K | -1.28M |
| IssuanceOfDebt | 7.08M | 943.00K | 10.02M | 0.00 |
| IssuanceOfCapitalStock | 5.91M | 9.29M | 22.70M | 36.98M |
| CapitalExpenditure | -3.00K | -10.00K | -7.00K | |
| InterestPaidSupplementalData | 374.00K | 885.00K | 0.00 | |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | |
| EndCashPosition | 1.44M | 4.59M | 20.05M | 27.61M |
| BeginningCashPosition | 4.59M | 20.05M | 27.61M | 1.86M |
| ChangesInCash | -3.15M | -15.46M | -7.55M | 25.75M |
| FinancingCashFlow | 7.49M | 6.20M | 32.21M | 63.46M |
| CashFlowFromContinuingFinancingActivities | 7.49M | 6.20M | 32.21M | 63.46M |
| NetOtherFinancingCharges | -896.00K | 11.05M | ||
| ProceedsFromStockOptionExercised | 3.97M | 0.00 | 10.00K | 16.70M |
| NetPreferredStockIssuance | 0.00 | 1.17M | 0.00 | 0.00 |
| PreferredStockIssuance | 0.00 | 1.17M | 0.00 | 0.00 |
| NetCommonStockIssuance | 5.91M | 8.12M | 22.70M | 36.98M |
| CommonStockIssuance | 5.91M | 8.12M | 22.70M | 36.98M |
| NetIssuancePaymentsOfDebt | -1.50M | -3.09M | 9.50M | -1.28M |
| NetShortTermDebtIssuance | -518.00K | -1.28M | ||
| ShortTermDebtPayments | -518.00K | -1.28M | ||
| NetLongTermDebtIssuance | -1.50M | -3.09M | 9.50M | 0.00 |
| LongTermDebtPayments | -8.57M | -4.04M | -518.00K | -1.28M |
| LongTermDebtIssuance | 7.08M | 943.00K | 10.02M | 0.00 |
| InvestingCashFlow | 0.00 | -3.00K | -10.00K | -7.00K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -3.00K | -10.00K | -7.00K |
| NetPPEPurchaseAndSale | 0.00 | -3.00K | -10.00K | -7.00K |
| PurchaseOfPPE | 0.00 | -3.00K | -10.00K | -7.00K |
| OperatingCashFlow | -10.64M | -21.66M | -39.76M | -37.70M |
| CashFlowFromContinuingOperatingActivities | -10.64M | -21.66M | -39.76M | -37.70M |
| ChangeInWorkingCapital | 5.29M | 5.16M | 699.00K | -4.90M |
| ChangeInPayablesAndAccruedExpense | 4.79M | 2.12M | 1.33M | -920.00K |
| ChangeInAccruedExpense | 10.01M | -531.00K | 2.94M | -901.00K |
| ChangeInPayable | -5.22M | 2.65M | -1.61M | -19.00K |
| ChangeInAccountPayable | -5.22M | 2.65M | -1.61M | -19.00K |
| ChangeInPrepaidAssets | 503.00K | 3.04M | -632.00K | -4.81M |
| ChangeInReceivables | 0.00 | 831.00K | ||
| ChangesInAccountReceivables | 0.00 | 831.00K | ||
| OtherNonCashItems | 5.77M | 2.96M | -4.08M | 54.28M |
| StockBasedCompensation | 486.00K | 387.00K | 3.63M | 7.79M |
| DepreciationAmortizationDepletion | 5.00K | 5.00K | 4.00K | 2.00K |
| DepreciationAndAmortization | 5.00K | 5.00K | 4.00K | 2.00K |
| Depreciation | 5.00K | 5.00K | 4.00K | 2.00K |
| OperatingGainsLosses | 2.94M | -20.00K | -255.00K | -1.81M |
| GainLossOnInvestmentSecurities | 1.66M | -20.00K | -255.00K | -1.69M |
| NetIncomeFromContinuingOperations | -25.13M | -30.15M | -39.75M | -93.06M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NRXP
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|